An interventional study of bicycle ergometer training with different intensities in Prehabilitation, sponsored by Medical University of Vienna. Status unknown. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-05.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Supportive care
In 2016, 2216 Austrian women (= 10% of all new cancer cases) were diagnosed with gynecological tumors. Depending on stage and entity, a main primary therapy option is the surgical tumor resection. In the phase of Prehabilitation (= the time frame from diagnosis to surgical intervention) supportive therapy options such as individualized exercise interventions potentially improve recovery and postoperative outcomes after surgical interventions. The primary aim of this study is to investigate the feasibility and acceptance of a prehabilitation training intervention with high-intensity interval training compared to a conventional moderate intensity continuous training and a non-training collective. Secondary goals are the investigation of the effectiveness of threshold-based intensity prescriptions and the impact on quality of life, fatigue, anxiety, depression, sexuality and ability to work.
Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: bicycle ergometer training with different intensities
Other: bicycle ergometer training with different intensities
Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
adherence to the exercise intervention
rate of completed exercise sessions as a measure of feasibility and acceptance
Time frame: 4 to 8 weeks
cardiovascular fitness
determined by VO2max
Time frame: 4 to 8 Weeks
workability
determined by the workability index questionnaire; minimum value 7, maximum value 49, higher values indicating better results
Time frame: 4 to 8 weeks
Health related Quality of life: questionnaire
determined by the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire, minimum value 30, maximum value 126, higher scores indicating higher quality of life
Time frame: 4 to 8 weeks
Anxiety and depression
determined by the Hospital Anxiety and Depression Scale questionnaire, minimum value 14, maximum value 56, higher values indicating higher depression levels
Time frame: 4 to 8 weeks
handgrip strength
determined by the handgrip dynamometer
Time frame: 4 to 8 weeks
body composition
determined by bioimpedance analysis
Time frame: 4 to 8 weeks
Cholesterol
Laboratory parameter in mg/ml as a part of the evaluation for cardiovascular risk factors
Time frame: 4 to 8 weeks
Thyreoglobulin
Laboratory parameter in µg/ml as a part of the evaluation for cardiovascular risk factors
Time frame: 4 to 8 weeks
hemoglobin A1c
Laboratory parameter in % as a part of the evaluation for cardiovascular risk factors
Time frame: 4 to 8 weeks
Brain natriuretic peptide
Laboratory parameter in pg/ml as a part of the evaluation for cardiovascular risk factors
Time frame: 4 to 8 weeks
Troponin T
Laboratory parameter in µg/ml as a part of the evaluation for cardiovascular risk factors
Time frame: 4 to 8 weeks
Creatin Kinase
Laboratory parameter in U/l as a part of the evaluation for cardiovascular risk factors
Time frame: 4 to 8 weeks
C-reactive protein
Laboratory parameter in mg/l as a part of the evaluation for inflammation
Time frame: 4 to 8 weeks
interleukin 1
Laboratory parameter in ng/ml as a part of the evaluation for inflammation
Time frame: 4 to 8 Weeks
interleukin 6
Laboratory parameter in ng/ml as a part of the evaluation for inflammation
Time frame: 4 to 8 weeks
Tumor Necrosis Factor alpha
Laboratory parameter in pg/ml as a part of the evaluation for inflammation
Time frame: 4 to 8 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna